ABUS

Arbutus Biopharm

3.47

0.06+1.76%

After Hours: 3.470 0.00 0.00%16:36 08/06 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE3.440/3.410

TODAY RANGE3.330-3.550

VOL1.30M

MARKET CAP664.60M

52 WEEK RANGE2.705-4.725

AVG VOL (3M)770.43K

% TURNOVER0.68%

TURNOVER--

P/E (TTM)-8.5827

% RANGE6.45%

EPS(TTM)-0.4043

P/E(FORWARD)-12.5271

P/B8.39

BVPS0.4134

DIVIDEND--

P/S106.77

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP518.93M

SHARES OUTSTANDING191.53M

NEXT EARNINGS08/06-08/11

FREE FLOAT149.55M

LOT SIZE1

EX-DATE11/04/2010

News

Press Releases

Financial Reports

Profile

Reuters·9h ago
Arbutus Biopharma Corp. Files Initial Statement of Beneficial Ownership for Director Roger Sawhney
Reuters·16h ago
Arbutus Biopharma Corp reports results for the quarter ended June 30 - Earnings Summary
TipRanks·17h ago
Arbutus Biopharma Appoints New Board Member Amid Strong Q2
Seeking Alpha·18h ago
Arbutus Biopharma GAAP EPS of $0.01 beats by $0.06, revenue of $10.74M
TipRanks·18h ago
Arbutus Biopharma reports Q2 EPS 1c vs (11c) last year
Dow Jones·18h ago
*Arbutus Biopharma 2Q Research and Development Expenses $5.5M >ABUS
Reuters·18h ago
Arbutus Biopharma Reports Q2 2025 Revenue Surge to $10.7M, Achieves Net Income of $2.5M, EPS at $0.01
Dow Jones·18h ago
*Arbutus Biopharma 2Q Net $2.52M >ABUS
Dow Jones·18h ago
*Arbutus Biopharma 2Q Rev $10.7M >ABUS
Dow Jones·18h ago
*Arbutus Biopharma 2Q EPS 1c >ABUS
Reuters·07/28 11:50
Arbutus Biopharma Corp <ABUS.OQ> expected to post a loss of 5 cents a share - Earnings Preview
TipRanks·07/18 16:22
Arbutus Biopharma’s AB-101 Study: A Potential Game-Changer in Chronic Hepatitis B Treatment
NASDAQ·06/25 12:12
Arbutus Biopharma Reacquires China Rights To Imdusiran
TipRanks·06/25 11:59
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical

Same Industry

Name/Symbol

Change%

Price

Regeneron Pharmaceuticals

REGN

-2.59%

555.13

Entero Therapeutics

ENTO

+6.59%

0.4400

BIONTECH

BNTX

+0.21%

111.30

United Therapeutics Corp.

UTHR

-0.79%

302.41

Vertex Pharmaceuticals Inc

VRTX

+2.85%

385.65

Siga Technologie

SIGA

+10.00%

7.26

Moderna

MRNA

-2.77%

26.71

Charles Riv Labs Intl Inc

CRL

-10.25%

150.33

Medpace Holdings

MEDP

-1.36%

430.37

Talphera Inc

TLPH

+1.50%

0.3989

ICON PLC

ICLR

-6.36%

155.42

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-3.50%

177.49

MOLECULAR PARTNERS AG

MOLN

-11.68%

3.48

Arcturus Therape

ARCT

+3.21%

12.21

Gilead Sciences Inc

GILD

-1.94%

110.28

PRA Health

PRAH

165.21

Incyte Corp

INCY

-0.10%

77.65

Aptevo Therapeutics Inc

APVO

-11.43%

2.17

Biospecifics

BSTC

+0.15%

88.53

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English